Charles G. Lineberry, Ph.D.
Chief Scientific Officer

As Chief Scientific Officer for the product development business unit, Charles Lineberry plays an active role in consulting on drug development strategies for Constella clients, overseeing the design and management of clinical trial programs and the preparation of multiple regulatory submissions (INDs and NDAs), clinical study reports, clinical development plans, and other non-regulatory writing projects. He has broad therapeutic experience and is a frequent speaker on issues related to minimizing placebo response and overcoming challenges in psychiatric and analgesic drug development.

The Co-Founder and former Chief Executive Officer of Lineberry Research Associates (LRA), acquired by Constella in November 2006, Lineberry has NIH post-doctoral training in neurobiology. He has more than 30 years of professional experience in biomedical research, including more than 25 years in clinical drug development for the pharmaceutical industry. Prior to the founding of LRA, Lineberry headed Clinical Neurosciences at Burroughs Wellcome Co. (now GlaxoSmithKline) and was responsible for the development of compounds in psychiatry, neurology, and anesthesiology. Under his leadership, his staff was responsible for the submission of 18 INDs and 8 approved NDAs. His experience includes both domestic and international drug development.

Earlier in his career, Lineberry held teaching and research positions in the medical schools at the University of Florida in Gainesville and the University of Pittsburgh. Lineberry received a B.A. in psychology and a Ph.D. in physiological psychology from the University of Delaware.